XML 39 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating Activities    
Net income (loss) $ 7,610us-gaap_NetIncomeLoss $ (20,682)us-gaap_NetIncomeLoss
Adjustments to reconcile net income(loss) to net cash used in operating activities    
Depreciation 56us-gaap_Depreciation 12us-gaap_Depreciation
Amortization of premium and discounts on investment securities 991us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium  
Share-based compensation 5,054us-gaap_ShareBasedCompensation 2,729us-gaap_ShareBasedCompensation
Changes in operating assets and liabilities:    
Due from Novartis Pharma, AG (49,289)us-gaap_IncreaseDecreaseInContractReceivablesNet  
Prepaid expense and other current assets (88)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 1,535us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accrued interest receivable (447)us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet  
Other assets 21us-gaap_IncreaseDecreaseInOtherNoncurrentAssets  
Accrued research and development expenses 185opht_IncreaseDecreaseInAccruedResearchAndDevelopment 317opht_IncreaseDecreaseInAccruedResearchAndDevelopment
Accounts payable and accrued expenses (3,924)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (57)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Deferred revenue 8,322us-gaap_IncreaseDecreaseInDeferredRevenue  
Net cash used in operating activities (31,509)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (16,146)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Investing Activities    
Purchase of marketable securities (144,433)us-gaap_PaymentsToAcquireMarketableSecurities (224,247)us-gaap_PaymentsToAcquireMarketableSecurities
Maturities of marketable securities 174,000us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities  
Purchase of property and equipment (64)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (728)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash provided by (used in) investing activities 29,503us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (224,975)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Financing Activities    
Proceeds from stock option/warrant exercises 1,760opht_ProceedsFromStockOptionsAndWarrantsExercised 11opht_ProceedsFromStockOptionsAndWarrantsExercised
Proceeds from follow-on public offering, net   55,409opht_ProceedsFromFollowOnPublicOfferingNet
Proceeds from royalty purchase agreement   41,667us-gaap_ProceedsFromOtherDebt
Net cash provided by financing activities 1,760us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 97,087us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net change in cash and cash equivalents (246)us-gaap_NetCashProvidedByUsedInContinuingOperations (144,034)us-gaap_NetCashProvidedByUsedInContinuingOperations
Cash and cash equivalents    
Beginning of period 39,814us-gaap_CashAndCashEquivalentsAtCarryingValue 210,596us-gaap_CashAndCashEquivalentsAtCarryingValue
End of period 39,568us-gaap_CashAndCashEquivalentsAtCarryingValue 66,562us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosures of non-cash information related to investing activities    
Change in unrealized gains in available for sale securities, net of tax $ 48us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax $ 18us-gaap_AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax